Oruka Therapeutics, Inc. Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA

Classifica tra le azioni #3289
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Prezzo delle azioni
$81.40
Capitalizzazione di mercato
$5.39B
Variazione (1 giorno)
1.86%
Variazione (1 anno)
205.46%
Paese
US
Scambia Oruka Therapeutics, Inc. (ORKA)

Categoria

Healthcare
Rapporto P/S per Oruka Therapeutics, Inc. (ORKA)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Oruka Therapeutics, Inc., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per Oruka Therapeutics, Inc. da 2005 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 2.08 -96.07%
2006 52.93 -91.38%
2005 614.26 0.00%
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
10.02 -
US
40.55 -
US
4.19 -
AU
10.44 -
NL
4.52 -
BE